Esperion to Participate in the 2022 Jefferies Global Healthcare Conference
June 02, 2022 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming 2022 Jefferies...
Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors
June 01, 2022 16:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 01, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of J. Martin Carroll as Chairperson of Esperion’s Board of Directors. Mr. Carroll will...
Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions
May 31, 2022 08:00 ET
|
Esperion Therapeutics, Inc.
– Highlight of accepted abstracts includes new real-world data on lipid-lowering therapy usage, submitted in partnership with UT Southwestern – – Accepted abstracts showcase breadth of Esperion’s...
Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference
May 17, 2022 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will participate in a fireside chat at the...
Esperion Reports First Quarter 2022 Financial Results and Provides Company Update
May 03, 2022 07:00 ET
|
Esperion Therapeutics, Inc.
– Unprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation– – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew...
Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology
May 02, 2022 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from the CLEAR Harmony Open-Label Extension (OLE) Study of bempedoic acid, also...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 29, 2022 17:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 29, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on April 28, 2022, the Compensation Committee of Esperion’s Board of Directors granted 14 new...
Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors
April 28, 2022 16:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 28, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Stephen Rocamboli as a Class I director, with a term expiring at the 2023 annual...
Esperion Supports Collaborative Study with an Integrated and Learning Health Care Delivery System in Northern California to Study the Effects of NEXLIZET® (bempedoic acid and ezetimibe) in Reducing LDL-Cholesterol Following a Recent Acute Coronary Syndrome Event
April 25, 2022 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 25, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced support for a study to evaluate the effects of bempedoic acid and ezetimibe (NEXLIZET) on short-term...
Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo
April 03, 2022 12:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL®) at the American...